Please Wait.....
Report
MEA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 334 Pages I Data Bridge Market Research
Middle East and Africa Kidney Cancer Diagnostics Market is projected to register a CAGR of 4.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Middle East and Africa Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, and the Rest of Middle East and Africa), Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:
- Rising healthcare expenditure for better health services
- Growing demand for better quality healthcare
- Growing prevalence of kidney cancer
Market Players
Some of the key market players for Middle East and Africa kidney cancer diagnostics market are listed below:
- BD
- BioVendor R&D
- Canon Medical Systems Corporation
- CENTOGENE N.V.
- FUJIFILM Corporation
- GeneDx,LLC
- Illumina, Inc.
- Invitae Corporation
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Qiagen
- Seimens Healthcare GmbH
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111
5 INDUSTRY INSIGHTS 112
6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114
7 MARKET OVERVIEW 117
7.1 DRIVERS 119
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127
8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128
8.1 OVERVIEW 129
8.2 IMAGING 133
8.2.1 COMPUTED TOMOGRAPHY 134
8.2.2 ULTRASOUND 134
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
8.2.4 ANGIOGRAPHY 134
8.2.5 X-RAY 134
8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
8.4.1 FINE NEEDLE ASPIRATION 136
8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
8.5.1 AQUAPORIN 1 (AQP1) 138
8.5.2 PERILIPIN (PLIN2) 138
8.5.3 N-METHYLTRANSFERASE (NMNT) 138
8.5.4 L-PLASTIN (LCP-1) 138
8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139
9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141
9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147
10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148
10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
10.2.1 IMAGING 154
10.2.2 BLOOD TEST 154
10.2.3 BIOPSY 154
10.2.4 BIOMARKER TEST 154
10.2.5 GENETIC TEST 154
10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
10.3.1 IMAGING 156
10.3.2 BLOOD TEST 156
10.3.3 BIOPSY 156
10.3.4 BIOMARKER TEST 156
10.3.5 GENETIC TEST 156
10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
10.4.1.1 IMAGING 158
10.4.1.2 BLOOD TEST 158
10.4.1.3 BIOPSY 158
10.4.1.4 BIOMARKER TEST 158
10.4.1.5 GENETIC TEST 158
10.4.1.6 OTHERS 158
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
10.4.2.1 IMAGING 159
10.4.2.2 BLOOD TEST 159
10.4.2.3 BIOPSY 159
10.4.2.4 BIOMARKER TEST 159
10.4.2.5 GENETIC TEST 159
10.4.2.6 OTHERS 159
11 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160
11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
11.2.1 IMAGING 166
11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
11.3.1 NEXT GENERATION SEQUENCING 168
11.3.2 MICROARRAYS 168
11.3.3 PCR 169
11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
11.4.1 RENAL CANCER PANELS 171
11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171
12 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172
12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179
13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181
13.1 OVERVIEW 182
13.2 SCREENING 185
13.2.1 INSTRUMENT BASED PRODUCTS 186
13.2.2 PLATFORM BASED PRODUCTS 186
13.2.3 KITS AND REAGENTS 186
13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
13.3.1 INSTRUMENT BASED PRODUCTS 187
13.3.2 PLATFORM BASED PRODUCTS 187
13.3.3 KITS AND REAGENTS 187
13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
13.4.1 INSTRUMENT BASED PRODUCTS 189
13.4.2 PLATFORM BASED PRODUCTS 189
13.4.3 KITS AND REAGENTS 189
13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
13.5.1 INSTRUMENT BASED PRODUCTS 190
13.5.2 PLATFORM BASED PRODUCTS 190
13.5.3 KITS AND REAGENTS 190
13.5.4 OTHER CONSUMABLES 191
14 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192
14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199
15 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200
15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205
16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206
16.1 MIDDLE EAST AND AFRICA 207
16.1.1 SOUTH AFRICA 220
16.1.2 SAUDI ARABIA 227
16.1.3 BAHRAIN 235
16.1.4 U.A.E. 242
16.1.5 EGYPT 250
16.1.6 ISRAEL 258
16.1.7 KUWAIT 266
16.1.8 OMAN 274
16.1.9 QATAR 282
16.1.10 REST OF MIDDLE EAST AND AFRICA 290
17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 291
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 291
18 SWOT ANALYSIS 292
19 COMPANY PROFILE 293
19.1 CANON MEDICAL SYSTEMS CORPORATION 293
19.1.1 COMPANY SNAPSHOT 293
19.1.2 REVENUE ANALYSIS 293
19.1.3 COMPANY PROFILE 294
19.1.4 PRODUCT PORTFOLIO 294
19.1.5 RECENT DEVELOPMENT 294
19.2 KONINKLIJKE PHILIPS N.V. 295
19.2.1 COMPANY SNAPSHOT 295
19.2.2 REVENUE ANALYSIS 295
19.2.3 COMPANY PROFILE 296
19.2.4 PRODUCT PORTFOLIO 296
19.2.5 RECENT DEVELOPMENTS 297
19.3 GENERAL ELECTRIC COMPANY 298
19.3.1 COMPANY SNAPSHOT 298
19.3.2 REVENUE ANALYSIS 298
19.3.3 COMPANY PROFILE 299
19.3.4 PRODUCT PORTFOLIO 299
19.3.5 RECENT DEVELOPMENTS 300
19.4 SIEMENS HEALTHCARE GMBH 301
19.4.1 COMPANY SNAPSHOT 301
19.4.2 REVENUE ANALYSIS 301
19.4.3 COMPANY PROFILE 302
19.4.4 PRODUCT PORTFOLIO 302
19.4.5 RECENT DEVELOPMENT 303
19.5 GRAIL 304
19.5.1 COMPANY SNAPSHOT 304
19.5.2 PRODUCT PORTFOLIO 304
19.5.3 RECENT DEVELOPMENTS 304
19.6 AMBRY GENETICS 306
19.6.1 COMPANY SNAPSHOT 306
19.6.2 PRODUCT PORTFOLIO 306
19.6.3 RECENT DEVELOPMENT 306
19.7 BIOVENDOR R&D 307
19.7.1 COMPANY SNAPSHOT 307
19.7.2 PRODUCT PORTFOLIO 307
19.7.3 RECENT DEVELOPMENT 307
19.8 BLUEPRINT GENETICS OY. 308
19.8.1 COMPANY SNAPSHOT 308
19.8.2 PRODUCT PORTFOLIO 308
19.8.3 RECENT DEVELOPMENT 308
19.9 CD GENOMICS 309
19.9.1 COMPANY SNAPSHOT 309
19.9.2 PRODUCT PORTFOLIO 309
19.9.3 RECENT DEVELOPMENT 309
19.10 CENTOGENE N.V. 310
19.10.1 COMPANY SNAPSHOT 310
19.10.2 REVENUE ANALYSIS 310
19.10.3 PRODUCT PORTFOLIO 311
19.10.4 RECENT DEVELOPMENT 311
19.11 CREATIVE DIAGNOSTICS 312
19.11.1 COMPANY SNAPSHOT 312
19.11.2 PRODUCT PORTFOLIO 312
19.11.3 RECENT DEVELOPMENT 312
19.12 FUJIFILM CORPORATION 313
19.12.1 COMPANY SNAPSHOT 313
19.12.2 REVENUE ANALYSIS 313
19.12.3 PRODUCT PORTFOLIO 314
19.12.4 RECENT DEVELOPMENTS 314
19.13 GENEDX, LLC 315
19.13.1 COMPANY SNAPSHOT 315
19.13.2 REVENUE ANALYSIS 315
19.13.3 PRODUCT PORTFOLIO 316
19.13.4 RECENT DEVELOPMENT 316
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 317
19.14.1 COMPANY SNAPSHOT 317
19.14.2 PRODUCT PORTFOLIO 317
19.14.3 RECENT DEVELOPMENT 317
19.15 ILLUMINA, INC. 318
19.15.1 COMPANY SNAPSHOT 318
19.15.2 REVENUE ANALYSIS 318
19.15.3 PRODUCT PORTFOLIO 319
19.15.4 RECENT DEVELOPMENT 319
19.16 INVITAE CORPORATION 320
19.16.1 COMPANY SNAPSHOT 320
19.16.2 REVENUE ANALYSIS 320
19.16.3 PRODUCT PORTFOLIO 321
19.16.4 RECENT DEVELOPMENT 321
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 322
19.17.1 COMPANY SNAPSHOT 322
19.17.2 REVENUE ANALYSIS 322
19.17.3 PRODUCT PORTFOLIO 323
19.17.4 RECENT DEVELOPMENTS 323
19.18 MYRIAD GENETICS, INC. 324
19.18.1 COMPANY SNAPSHOT 324
19.18.2 REVENUE ANALYSIS 324
19.18.3 PRODUCT PORTFOLIO 325
19.18.4 RECENT DEVELOPMENT 325
19.19 THERMO FISHER SCIENTIFIC INC. 326
19.19.1 COMPANY SNAPSHOT 326
19.19.2 REVENUE ANALYSIS 326
19.19.3 PRODUCT PORTFOLIO 327
19.19.4 RECENT DEVELOPMENT 327
19.20 QIAGEN 328
19.20.1 COMPANY SNAPSHOT 328
19.20.2 REVENUE ANALYSIS 328
19.20.3 PRODUCT PORTFOLIO 329
19.20.4 RECENT DEVELOPMENT 329
20 QUESTIONNAIRE 330
21 RELATED REPORTS 334
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security